Core Viewpoint - Zhongtai Securities maintains a "Buy" rating for HBM Pharmaceuticals-B (02142), projecting revenue growth driven by licensing agreements and milestone payments from HBM7020 and HBM4003, with expected revenues of 1.4 billion, 1.594 billion, and 1.485 billion yuan from 2025 to 2027, and net profits of 666 million, 768 million, and 740 million yuan respectively [1] Group 1: Licensing Agreement and Financial Impact - On February 23, 2026, HBM Pharmaceuticals announced a licensing and equity cooperation agreement with Solstice Oncology, granting exclusive rights for HBM4003 outside Greater China, with upfront payments exceeding $105 million, including a $50 million upfront cash payment and $5 million in recent payments [1] - The agreement also includes potential milestone payments of up to $1.1 billion based on future development and regulatory achievements, along with tiered royalties based on net sales outside Greater China [1] Group 2: Product Characteristics and Clinical Potential - HBM4003 is the world's first fully human heavy-chain antibody targeting CTLA-4, showing enhanced antibody-dependent cellular cytotoxicity (ADCC) and high specificity for CTLA-4 expressing Treg cells in the tumor microenvironment, indicating potential for improved therapeutic efficacy and reduced toxicity [2] - In Phase I trials, HBM4003 demonstrated good safety and strong efficacy, with potential indications including melanoma, non-small cell lung cancer, hepatocellular carcinoma, and neuroendocrine tumors [3] Group 3: Cash Flow and Growth Outlook - The recent payment structure exceeding $105 million will directly enhance the company's cash flow, complementing previous profit forecasts of approximately $88 million to $95 million for 2025, thereby solidifying the company's financial stability and growth potential in the medium term [4]